SI2970232T1 - Substituirani derivati piridina uporabni kot inhibitorji C-FMS kinaze - Google Patents

Substituirani derivati piridina uporabni kot inhibitorji C-FMS kinaze Download PDF

Info

Publication number
SI2970232T1
SI2970232T1 SI201430613T SI201430613T SI2970232T1 SI 2970232 T1 SI2970232 T1 SI 2970232T1 SI 201430613 T SI201430613 T SI 201430613T SI 201430613 T SI201430613 T SI 201430613T SI 2970232 T1 SI2970232 T1 SI 2970232T1
Authority
SI
Slovenia
Prior art keywords
compound
formula
cancer
trimethyltetrahydro
dimethylcyclohex
Prior art date
Application number
SI201430613T
Other languages
English (en)
Inventor
Jie Chen
Matthew Donahue
Heng-Keang Lim
Ronghui Lin
Rhys Salter
Jiejun Wu
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI2970232T1 publication Critical patent/SI2970232T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)

Claims (14)

  1. Substituirani derivati piridina uporabni kot inhibitorji C-FMS kinaze Patentni zahtevki
    1. Spojina s formulo I
    kjer R1 je izbran iz skupine, ki vsebuje CH2-OH in -C(0)0H; ali njen enantiomer, diastereomer, racemat ali farmacevtsko sprejemljiva sol.
  2. 2. Spojina po zahtevku 1, kjer je R1 -C(0)OH.
  3. 3. Spojina po zahtevku 1, kjer je R1 -CH2-OH.
  4. 4. Spojina po zahtevku 1, kjer ima spojina formulo (I-M2)
    ali njen enantiomer, diastereomer, racemat ali farmacevtsko sprejemljiva sol; kjer je spojina s formulo (I-M2) prisotna v izolirani obliki ali v v bistvu čisti obliki, ali kjer ima spojina formulo (I-M7)
    ali njen enantiomer, diastereomer, racemat ali farmacevtsko sprejemljiva sol; kjer je spojina s formulo (I-M7) prisotna v izolirani obliki ali v v bistvu čisti obliki.
  5. 5. Mešanice spojine s formulo (I-M2-D4a)
    in spojine s formulo (I-M2-D4b)
    ali mešanica spojine s formulo (I-M7-D4a)
    in spojine s formulo (I-M7-D4b)
  6. 6. Farmacevtski sestavek, ki vsebuje farmacevtsko sprejemljiv nosilec in spojino po zahtevku 1.
  7. 7. Spojina, kot je opisana v zahtevku 1 ali spojina po zahtevku 6, za uporabo v postopku zdravljenja motnje, pri kateri posreduje cfms kinaza, kjer postopek vsebuje administracijo subjektu, ki to potrebuje, terapevtsko učinkovite količine spojine, kot je opisana v zahtevku 1 ali spojine po zahtevku 6.
  8. 8. Spojina, kot je opisana v zahtevku 1 ali spojina po zahtevku 6, za uporabo, kot jeopisano v zahtevku 7, kjer je motnja izbrana iz skupine, ki vsebuje osteoporozo, Pagetovo bolezen, revmatoidni artritis, druge oblike vnetnega artritisa, osteoartritis, odpoved proteze, osteolitični sarkom, mieloma, Hodgkinsov limfom, metastaze tumorja v kosti, rak jajčnikov, rak maternice, rak dojke, rak prostate, pljučni rak, rak črevesja, trebušni rak, levkemijo dlakavih celic, metataze od raka jajčnikov, rak maternice, rak dojke, rak prostate, pljučni rak, rak črevesja, trebušni rak ali levkemijo dlakavih celic, glomerulonefritis, vnetno črevesno bolezen, sarkoidozo, kongestivno obstruktivno pljučno bolezen, idiopatsko pljučno fibrozo, astmo, pankreatitis, okužbe s HIV, psoriazo, diabetes, angiogenezo, povezano s tumorjem, starostno degeneracijo makule, diabetično retinopatijo, restenozo, shizofrenijo, Alzheimerjevo demenco; bolečine, bolečine skeleta, ki jih povzročajo metastaze tumorja ali osteoartritis, nevrogene bolečine, avtoimunsko bolezen, sistemski lupus eritematozus, revmatoidni artritis, druge oblike vnetnega artritisa, psoriaza, Sjorgenov sindrom, multiplo sklerozo in uveitis ali kjer je motnja, pri kateri posreduje c-fms kinaza revmatoidni artritis ali kjer je motnja pri kateri posreduje c-fms kinaza Hodgkinsov limfom.
  9. 9. Postopek priprave spojine s formulo (I-M2)
    ali njenega enantiomera, diastereomera, racemata ali farmacevtsko sprejemljive soli; ki obsega
    reagiranje n-butil 4-(5-(4-ciano-l-((2-(trimetilsilil)etoksi)metil)-lH-imidazol-2-karboksamido)-6-(4,4-dimetilcikloheks-1 -en-1 -il)piridin-2-il)-2,6,6-trimetiltetrahidro-2H-piran-2-karboksilata s sredstvom za destilacijo; v organskem topilu; pri temperaturi v območju od približno 0°C do približno 120°C; da dobimo n-butil 4-(5-(4-ciano-lH-imidazol-2-karboksamido)-6-(4,4-dimetilcikloheks-l-en-l-il)piridin-2-il)-2,6,6-trimetiltetrahidro-2H-piran-2-karboksilat;
    reagiranje n-butil 4-(5-(4-ciano-lH-imidazol-2-karboksamido)-6-(4,4-dimetilcikloheks-l-en-l-il)piridin-2-il)-2,6,6-trimetiltetrahidro-2H-piran-2-karboksilata in kisline ali baze; da dobimo odgovarjajočo spojino s formulo (I-M2).
  10. 10. Postopek priprave spojine s formulo (I-M7)
    ali njenega enantiomera, diastereomera, racemata ali farmacevtsko sprejemljive soli; ki vsebuje
    reagiranje n-butil 4-(5-(4-ciano-1 -((2-(trimetilsilil)etoksi)metil)-1 H-imidazol-2-karboksamido )-6-(4,4-dimetilcikloheks-1 -en-1 -il)piridin-2-il)-2,6,6-trimetiltetrahidro-2H-piran-2-karboksilata z reducentom; v organskem topilu; pri temperaturi v območju od približno -80°C do približno 50°C; da dobimo 4-ciano-N-(2-(4,4-dimetilcikloheks-l-en-l-il)-6-(2-(hidroksimetil)-2,6,6-trimetiltetrahidro-2H-piran-4-il)piridin-3-il)-l-((2-(trimetilsilil)etoksi)metil)-lH-imidazol-2-karboksamid;
    reagiranje 4-ciano-N-(2-(4,4-dimetilcikloheks-1 -en-1 -il)-6-(2-(hidroksimetil)-2,6,6-trimetiltetrahidro-2H-piran-4-il)piridin-3-il)-1 -((2-(trimetilsilil)etoksi)metil)-lH-imidazol-2-karboksamida s sredstvom za destilacijo; v organskem topilu; pri temperaturi v območju od približno 0°C do približno 110°C; da dobimo odgovarjajočo spojino s formulo (I-M7).
  11. 11. Spojina po zahtevku 1, za uporabo kot zdravilo.
  12. 12. Spojina po zahtevku 1, izbrana iz skupine, ki vsebuje spojino s formulo (I-M2-2R,4S)
    in spojino s formulo (I-M2-2S,4R)
  13. 13. Spojina po zahtevku 1, izbrana iz skupine, ki vsebuje spojino s formulo (I-M7-2R,4S)
    in spojino s formulo (I-M7-2S,4R)
  14. 14. Spojina po kateremkoli zahtevku 1, 2, 3, 12 ali 13, kjer je spojina prisotna v izolirani obliki ali v v bistvu čisti obliki.
SI201430613T 2013-03-15 2014-03-13 Substituirani derivati piridina uporabni kot inhibitorji C-FMS kinaze SI2970232T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791007P 2013-03-15 2013-03-15
EP14729096.9A EP2970232B1 (en) 2013-03-15 2014-03-13 Substituted pyridine derivatives useful as c-fms kinase inhibitors
PCT/US2014/025308 WO2014151258A1 (en) 2013-03-15 2014-03-13 Substituted pyridine derivatives useful as c-fms kinase inhibitors

Publications (1)

Publication Number Publication Date
SI2970232T1 true SI2970232T1 (sl) 2018-03-30

Family

ID=50897867

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430613T SI2970232T1 (sl) 2013-03-15 2014-03-13 Substituirani derivati piridina uporabni kot inhibitorji C-FMS kinaze

Country Status (19)

Country Link
US (4) US9611259B2 (sl)
EP (2) EP2970232B1 (sl)
JP (1) JP6384022B2 (sl)
CN (2) CN105026388B (sl)
AU (1) AU2014235183B9 (sl)
CY (1) CY1120185T1 (sl)
DK (1) DK2970232T3 (sl)
ES (1) ES2662600T3 (sl)
HK (3) HK1212339A1 (sl)
HR (1) HRP20180632T1 (sl)
HU (1) HUE036925T2 (sl)
LT (1) LT2970232T (sl)
MX (1) MX365315B (sl)
NO (1) NO3090256T3 (sl)
PL (1) PL2970232T3 (sl)
PT (1) PT2970232T (sl)
RS (1) RS57103B1 (sl)
SI (1) SI2970232T1 (sl)
WO (1) WO2014151258A1 (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611259B2 (en) 2013-03-15 2017-04-04 Janssen Pharmaceutica Nv Substituted pyridine derivatives useful as C-FMS kinase inhibitors
TW201811326A (zh) * 2016-07-18 2018-04-01 比利時商健生藥品公司 ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
TWI752980B (zh) * 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
CN110636861B (zh) * 2017-03-03 2022-07-08 詹森生物科技公司 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1807077B1 (en) * 2004-10-22 2016-11-23 Janssen Pharmaceutica NV Inhibitors of c-fms kinase
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
JP2011502266A (ja) * 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｍｓ治療に対する応答を評価するバイオマーカー
US9611259B2 (en) * 2013-03-15 2017-04-04 Janssen Pharmaceutica Nv Substituted pyridine derivatives useful as C-FMS kinase inhibitors

Also Published As

Publication number Publication date
HK1250986A1 (zh) 2019-01-18
CN108341805A (zh) 2018-07-31
DK2970232T3 (en) 2018-04-09
PT2970232T (pt) 2018-05-09
US11214566B2 (en) 2022-01-04
NO3090256T3 (sl) 2018-03-03
HK1212339A1 (en) 2016-06-10
JP6384022B2 (ja) 2018-09-05
US10071991B2 (en) 2018-09-11
MX2015012343A (es) 2016-06-02
US10800764B2 (en) 2020-10-13
CY1120185T1 (el) 2018-12-12
US9611259B2 (en) 2017-04-04
RS57103B1 (sr) 2018-06-29
HRP20180632T1 (hr) 2018-06-01
LT2970232T (lt) 2018-04-10
US20180346454A1 (en) 2018-12-06
EP2970232B1 (en) 2018-02-14
US20170158678A1 (en) 2017-06-08
AU2014235183B9 (en) 2018-04-05
AU2014235183B2 (en) 2018-02-15
PL2970232T3 (pl) 2018-08-31
US20200399254A1 (en) 2020-12-24
HUE036925T2 (hu) 2018-08-28
EP2970232A1 (en) 2016-01-20
CN105026388A (zh) 2015-11-04
MX365315B (es) 2019-05-29
US20160016942A1 (en) 2016-01-21
JP2016512837A (ja) 2016-05-09
HK1258911A1 (zh) 2019-11-22
EP3284742A1 (en) 2018-02-21
ES2662600T3 (es) 2018-04-09
WO2014151258A1 (en) 2014-09-25
AU2014235183A1 (en) 2015-09-17
CN105026388B (zh) 2018-05-18

Similar Documents

Publication Publication Date Title
SI2970232T1 (sl) Substituirani derivati piridina uporabni kot inhibitorji C-FMS kinaze
JP5650735B2 (ja) タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体
KR102691467B1 (ko) Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
ES2828431T3 (es) Compuestos útiles como inhibidores de cinasa
IL256191A (en) New amino acid histories, the process for their preparation and the pharmaceutical preparations that contain them
KR101910720B1 (ko) 키나제 억제제로서의 아미노헤테로아릴 벤즈아미드
KR102644798B1 (ko) Erk1 및 erk2의 헤테로사이클릭 억제제 및 암 치료에서 이의 용도
CN107001260B (zh) 3-氧基-3-(芳氨基)丙酸酯、其制备方法、以及其在制备吡咯烷酮中的用途
AU777824B2 (en) Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
AU2018288018A1 (en) Small molecule modulators of human sting
JP2014506599A5 (sl)
KR102339227B1 (ko) Gsk-3 억제제
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
JP2015536307A5 (sl)
EP2668162A1 (en) Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
JP2015509535A5 (sl)
JP2022516469A (ja) ユビキチン特異的プロテアーゼ１を阻害するための組成物
CN104080774A (zh) 吡嗪甲酰胺化合物
EA020749B1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
EA023137B1 (ru) Модуляторы альфа 7 никотинового рецептора для лечения болевого синдрома, психического заболевания, когнитивного расстройства или болезни альцгеймера
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
JP2016529315A5 (sl)
Shiroodi et al. Synthesis of furans and pyrroles via migratory and double migratory cycloisomerization reactions of homopropargylic aldehydes and imines
SI3102573T1 (sl) Substituiran tiazol ali oksazol kot antagonisti receptorja p2x7
CN105367427A (zh) 手性1,2-二胺类化合物及其制备方法和应用